583 related articles for article (PubMed ID: 17554963)
1. [Bioequivalence studies of pharmaceutical preparations].
Vetchý D; Frýbortová K; Rabisková M; Danecková H
Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
[TBL] [Abstract][Full Text] [Related]
2. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
3. Types of bioequivalence and related statistical considerations.
Hauck WW; Anderson S
Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
[TBL] [Abstract][Full Text] [Related]
4. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
5. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
Verbeeck RK; Kanfer I; Walker RB
Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
[TBL] [Abstract][Full Text] [Related]
6. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence studies: single vs multiple dose.
Steinijans VW; Sauter R; Jonkman JH; Schulz HU; Stricker H; Blume H
Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S31-6. PubMed ID: 1601529
[TBL] [Abstract][Full Text] [Related]
8. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.
García-Arieta A; Morales-Alcelay S; Herranz M; de la Torre-Alvarado JM; Blázquez-Pérez A; Suárez-Gea ML; Alvarez C
Int J Pharm; 2012 Feb; 423(2):321-5. PubMed ID: 22120644
[TBL] [Abstract][Full Text] [Related]
9. Debate: Substitution of generic drugs in epilepsy: is there cause for concern?
Gidal BE; Tomson T
Epilepsia; 2008 Dec; 49 Suppl 9():56-62. PubMed ID: 19087118
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the bioavailability and bioequivalence of generic medications.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
[TBL] [Abstract][Full Text] [Related]
11. Quantitative assessment of the switchability of generic products.
Karalis V; Bialer M; Macheras P
Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
[TBL] [Abstract][Full Text] [Related]
12. What makes a generic medication generic?
Howland RH
J Psychosoc Nurs Ment Health Serv; 2009 Dec; 47(12):17-20. PubMed ID: 20000278
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem).
Leelarasamee A; Rongrungruang Y; Trakulsomboon S; Pongpech P; Thanawattanawanich P; Jithavech P
J Med Assoc Thai; 2008 Jul; 91(7):980-8. PubMed ID: 18839835
[TBL] [Abstract][Full Text] [Related]
14. Generic products of antiepileptic drugs (AEDs): is it an issue?
Bialer M
Epilepsia; 2007 Oct; 48(10):1825-32. PubMed ID: 17850324
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
Marzo A; Balant LP
Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
[TBL] [Abstract][Full Text] [Related]
16. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use].
Zapater P; Horga JF
Rev Neurol; 1999 Dec 16-31; 29(12):1235-46. PubMed ID: 10652753
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence and narrow therapeutic index drugs.
Benet LZ; Goyan JE
Pharmacotherapy; 1995; 15(4):433-40. PubMed ID: 7479195
[TBL] [Abstract][Full Text] [Related]
18. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
19. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
Quiroz J; Ting N; Wei GC; Burdick RK
Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of generic aerosol bronchodilators: what are the issues?
Spino M
CMAJ; 1989 Nov; 141(9):883-7. PubMed ID: 2804845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
